Skip to main content
OliX Pharmaceuticals, Inc. logo

OliX Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · 226950 ISIN · KR7226950004 KO Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2025-02-14 Report Publication Anno…
Country KR South Korea
Listing KO 226950

About OliX Pharmaceuticals, Inc.

https://olixpharma.com

OliX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the development of therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric siRNA (asiRNA) platform to create treatments that selectively silence disease-causing genes. Its research and development efforts are focused on building a robust pipeline of drug candidates targeting a variety of illnesses with high unmet medical needs. The pipeline has a particular emphasis on ophthalmic and dermal disorders, with key programs addressing conditions such as hypertrophic scars, age-related macular degeneration (AMD), and other fibrotic and ocular diseases.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Non-Deal Roadshow). It provides details such as the date, location, target audience, and purpose of the meeting. Since it is an announcement of an event rather than the presentation materials themselves, and it fits the criteria for a regulatory announcement regarding corporate activities, it is classified as a Regulatory Filing (RNS).
2025-02-14 Korean
투자판단관련주요경영사항 (OLX75016(OLX702A) 공동개발 및 라이선스 계약 체결)
M&A Activity Classification · 100% confidence The document is a regulatory filing from the company 'OliX' regarding a 'Collaboration and license agreement' with Eli Lilly. It details the terms of a major business contract, including the contract value, scope, and nature of the partnership. This type of disclosure regarding significant business developments, partnerships, or licensing agreements is classified as a general regulatory filing (RNS) in the absence of a more specific category like M&A (which usually implies a takeover or merger) or specific financial reporting.
2025-02-07 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required when an entity's shareholding in a listed company crosses certain thresholds (typically 5%). The text explicitly mentions '자본시장과 금융투자업에 관한 법률 제147조' (Article 147 of the Capital Markets Act) and details the shareholding changes of Mirae Asset Global Investments in the company 'OliX'. This falls under the category of Major Shareholding Notification.
2025-02-03 Korean
투자판단관련주요경영사항(임상시험결과) (안드로겐성 탈모가 있는 건강한 남성을 대상으로 OLX72021의 안전성, 내약성 및 약동학적 특성을 평가하기 위한 다기관, 무작위배정, 이중눈가림, 단일용량상승, 위약대조, 제1상 임상시험 결과보고서(CSR) 수령)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from a Korean company (OliX Pharmaceuticals) submitted to the KRX (Korea Exchange). It details the receipt of a Clinical Study Report (CSR) for a Phase 1 clinical trial. Since this is a mandatory disclosure of material business information regarding clinical trial results, and it does not fit into specific categories like 'Earnings Release' or 'Annual Report', it falls under the 'Regulatory Filings' category as a general corporate announcement.
2025-01-10 Korean
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification regarding the exercise of conversion rights (전환청구권행사) for convertible bonds issued by the company. It details the number of shares to be issued, the conversion price, and the remaining balance of the convertible bonds. This type of filing relates to changes in capital structure due to the conversion of debt into equity, which falls under the category of Share Issue/Capital Change.
2024-12-17 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for the purpose of determining shareholders eligible to vote at the 15th Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of a corporate action (setting a record date). Given the nature of the announcement as a regulatory disclosure regarding shareholder rights for an upcoming meeting, it fits best under the general regulatory filing category.
2024-12-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.